Dossiers under build
Additional lanes — not yet authorized.
Each lane below is in dossier build. None carry authorized comparative-lift or lead-time claims. Named states are provisional until Validation gates are cleared.
- SGLT2 Class — HF + CKD Generalization probe Named state: Threshold transferability cleared Hardening signal at 0.73 on curate-v1. Gate at 0.65. Cross-lane transfer tested; authorized-exhibit gate not yet cleared for this lane family.
- Bluebird bio / Vertex Pharmaceuticals Tier 1 dossier Named state: Under build Platform divergence in safety-claim stability under contestation. Pre-rejection stress detected on durability framing. Dossier build in progress — no authorized read.
- Sarepta Therapeutics Tier 1 dossier Named state: Under build Pre-rejection stress on durability framing under active monitoring. Dossier build in progress — no authorized read.
- Oxbryta (Pfizer / GBT) Tier 1 dossier Named state: Approved-claim decay Post-withdrawal claim decay trajectory under reconstruction. Dossier build in progress — no authorized read.
- Applied Therapeutics Tier 1 dossier Named state: Re-hardening after CRL CRL-response claim re-hardening under reconstruction. Dossier build in progress — no authorized read.
- Blenrep (GSK) Tier 1 dossier Named state: Under build Withdrawal-to-reintroduction claim trajectory. Dossier build in progress — no authorized read.
What this page does not say
- These cases are dossier builds in progress. They are not authorized comparative-lift claims.
- Lead-time figures are not stated on this page. The active External-Claim Freeze is documented in Validation.
- A hardened claim can still be wrong. Hardening measures institutional resistance to change, not truth.
- The observation instrument is Wikipedia revision history. It is not public opinion, sentiment, or the external outcome stream.
Action
Request a private brief on one lane.
One lane, one decision window, one circulatable artifact. Bounded review, not open-ended monitoring.